STOCK TITAN

Geron Corporation Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags

Geron (GERN) reported Q3 2024 financial results, achieving $28.2 million in RYTELO™ net product revenue in its first full quarter of sales. The company secured $250 million in financing through agreements with Royalty Pharma and Pharmakon Advisors, with access to an additional $125 million in debt. Q3 net loss was $26.4 million, or $0.04 per share. Total operating expenses were $56.5 million. The company expects 2024 total operating expenses between $260-270 million. Cash position as of September 30, 2024, was $378.9 million, with pro forma cash of $542.4 million including recent financing proceeds.

Geron (GERN) ha riportato i risultati finanziari del terzo trimestre del 2024, registrando 28,2 milioni di dollari di ricavi netti da prodotto RYTELO™ nel suo primo trimestre completo di vendite. L'azienda ha ottenuto 250 milioni di dollari di finanziamenti tramite accordi con Royalty Pharma e Pharmakon Advisors, con accesso a ulteriori 125 milioni di dollari in debito. La perdita netta del terzo trimestre è stata di 26,4 milioni di dollari, pari a 0,04 dollari per azione. Le spese operative totali sono ammontate a 56,5 milioni di dollari. L'azienda prevede che le spese operative totali per il 2024 siano comprese tra 260-270 milioni di dollari. La posizione di cassa al 30 settembre 2024 era di 378,9 milioni di dollari, con una cassa pro forma di 542,4 milioni di dollari che include i proventi del recente finanziamento.

Geron (GERN) reportó los resultados financieros del tercer trimestre de 2024, logrando 28,2 millones de dólares en ingresos netos de producto RYTELO™ en su primer trimestre completo de ventas. La empresa aseguró 250 millones de dólares en financiamiento a través de acuerdos con Royalty Pharma y Pharmakon Advisors, con acceso a 125 millones de dólares adicionales en deuda. La pérdida neta del tercer trimestre fue de 26,4 millones de dólares, o 0,04 dólares por acción. Los gastos operativos totales fueron de 56,5 millones de dólares. La compañía espera que los gastos operativos totales para 2024 estén entre 260-270 millones de dólares. La posición de efectivo al 30 de septiembre de 2024 era de 378,9 millones de dólares, con efectivo pro forma de 542,4 millones de dólares incluyendo los ingresos del financiamiento reciente.

Geron (GERN)은 2024년 3분기 재무 결과를 발표하며, 첫 전체 판매 분기에서 2,820만 달러의 RYTELO™ 순제품 수익을 달성했습니다. 회사는 Royalty Pharma 및 Pharmakon Advisors와의 계약을 통해 2억 5천만 달러의 자금을 확보했으며, 추가로 1억 2,500만 달러의 채무 접근을 가능하게 했습니다. 3분기 순손실은 2,640만 달러로, 주당 0.04달러에 해당합니다. 총 운영 비용은 5,650만 달러였습니다. 회사는 2024년 총 운영 비용을 2억 6천만~2억 7천만 달러로 예상하고 있습니다. 2024년 9월 30일 현재 현금 보유액은 3억 7,890만 달러였으며, 최근 자금조달 수익을 포함한 프로 포르마 현금은 5억 4,240만 달러입니다.

Geron (GERN) a annoncé les résultats financiers du troisième trimestre 2024, atteignant 28,2 millions de dollars de revenus nets de produit RYTELO™ lors de son premier trimestre complet de ventes. La société a obtenu 250 millions de dollars de financement grâce à des accords avec Royalty Pharma et Pharmakon Advisors, avec un accès à 125 millions de dollars supplémentaires en dette. La perte nette du troisième trimestre était de 26,4 millions de dollars, soit 0,04 dollar par action. Les dépenses d'exploitation totales s'élevaient à 56,5 millions de dollars. La société s'attend à ce que les dépenses d'exploitation totales pour 2024 se chiffrent entre 260-270 millions de dollars. La position de trésorerie au 30 septembre 2024 était de 378,9 millions de dollars, avec une trésorerie pro forma de 542,4 millions de dollars incluant les produits de financement récents.

Geron (GERN) hat die finanziellen Ergebnisse des dritten Quartals 2024 berichtet und erzielte 28,2 Millionen Dollar an Netto-Umsatz mit RYTELO™ im ersten vollen Verkaufsquartal. Das Unternehmen sicherte sich 250 Millionen Dollar an Finanzierung durch Vereinbarungen mit Royalty Pharma und Pharmakon Advisors und hat Zugang zu zusätzlichen 125 Millionen Dollar an Schulden. Der Nettoverlust im dritten Quartal betrug 26,4 Millionen Dollar, was 0,04 Dollar pro Aktie entspricht. Die Gesamtausgaben betrugen 56,5 Millionen Dollar. Das Unternehmen erwartet für 2024 Gesamtausgaben zwischen 260-270 Millionen Dollar. Die Barreserven zum 30. September 2024 betrugen 378,9 Millionen Dollar, mit einer pro forma Barreserve von 542,4 Millionen Dollar, einschließlich der Erlöse aus der jüngsten Finanzierung.

Positive
  • Strong Q3 2024 RYTELO revenue of $28.2 million in first full quarter
  • Secured $250 million in financing with access to additional $125 million
  • Reduced Q3 net loss to $26.4 million from $44.8 million year-over-year
  • Healthy cash position of $542.4 million (pro forma)
Negative
  • Operating expenses increased to $56.5 million from $47.8 million year-over-year
  • SG&A expenses rose to $35.9 million from $18.4 million year-over-year
  • Interest expense increased to $3.0 million from $2.1 million year-over-year

Insights

The Q3 results showcase strong commercial momentum for Geron, with $28.2 million in RYTELO net product revenue in its first full quarter - an impressive start for a newly launched drug. The company significantly strengthened its balance sheet through $250 million in financing deals with Royalty Pharma and Pharmakon Advisors, with access to an additional $125 million.

Pro forma cash position of $542.4 million provides substantial runway. Operating expenses of $56.5 million for Q3 and net loss of $26.4 million ($0.04 per share) show improved efficiency compared to prior year. The $260-270 million operating expense guidance for 2024 appears well-funded given the cash position and growing revenue stream.

The strong initial RYTELO sales indicate significant market penetration in lower-risk MDS, validating the commercial potential. The pending EU regulatory decision expected in late 2024/early 2025 represents a major growth catalyst, with planned commercialization in select EU markets by 2026. The appointment of an experienced CCO signals commitment to global commercial expansion.

The financing deals with favorable terms demonstrate institutional confidence in RYTELO's market potential. The upcoming Phase 3 IMpactMF trial interim analysis in early 2026 could expand the addressable market into relapsed/refractory MF, representing another significant growth opportunity.

Achieved $28.2 million in RYTELO™ (imetelstat) net product revenue in first full quarter of sales

Received $250 million in gross proceeds from synthetic royalty and debt financings with Royalty Pharma and Pharmakon Advisors, with access to an additional $125 million in debt

FOSTER CITY, Calif.--(BUSINESS WIRE)-- Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today reported financial results for the third quarter of 2024 and recent business highlights.

“This has been a transformative year for Geron, following our first FDA approval and commercial launch of RYTELO in June. The initial full quarter of product revenue from our U.S. launch exceeded our expectations and demonstrates strong execution as a commercial company. These results also reflect the high unmet need in lower-risk MDS and the compelling value proposition of RYTELO for hematologists and patients, giving us confidence in future continued demand and momentum for RYTELO,” said John A. Scarlett, M.D., Geron’s Chairman and Chief Executive Officer. “We were also pleased to announce this morning the completion of important synthetic royalty and debt financing transactions with Royalty Pharma and Pharmakon Advisors. We believe that the favorable terms in these transactions reflect the significant commercial potential of RYTELO and provide us with critical flexibility to fuel continued growth and invest in our future.”

Recent Business Highlights

  • Strong execution in the first full quarter of U.S. launch, with net product revenue for RYTELO (imetelstat) of $28.2 million in the third quarter of 2024.
  • In November 2024, completed synthetic royalty and debt financing transactions to strengthen our cash position and further solidify our balance sheet while providing strategic flexibility to invest in our future. We entered into a synthetic royalty agreement with Royalty Pharma providing $125 million of capital in exchange for tiered royalty payments. We also entered into a 5-year, senior term loan agreement with Pharmakon for up to $250 million, from which we have drawn a first tranche of $125 million, a portion of which was used to fully repay amounts owed under our existing loan with Hercules Capital, Inc. and Silicon Valley Bank ($86.5 million), which has now been terminated, with the ability to borrow another $125 million prior to the end of 2025, subject to specified conditions.
  • Jim Ziegler appointed as Executive Vice President, Chief Commercial Officer in September 2024, to spearhead Geron’s global commercial strategy and operations, lead the commercial organization and be responsible for driving growth of RYTELO. Mr. Ziegler brings more than 25 years of commercial experience in the biopharmaceutical industry, spanning leadership, strategic and operational roles in both large and smaller organizations.
  • New data to be presented at upcoming American Society for Hematology (ASH) Annual Meeting highlights the potential of imetelstat in myeloid hematologic malignancies (please view ASH press release for more details).

Upcoming Milestones

  • We expect review of the Marketing Authorization Application (MAA) for RYTELO in lower-risk MDS by the Committee for Medicinal Products for Human Use (CHMP) could be completed in late 2024 or early 2025, with potential approval by the European Commission in the first half of 2025. We are continuing to prepare for the potential launch of RYTELO in the EU, and subject to regulatory approval, are planning to commercialize RYTELO in select EU markets commencing in 2026.
  • We expect an interim analysis from the Phase 3 IMpactMF trial in patients with relapsed/refractory MF may occur in early 2026 (when approximately 35% of planned enrolled patients have died) and the final analysis may occur in early 2027 (when approximately 50% of planned enrolled patients have died), based on our most recent planning assumptions for enrollment and death rates in the trial.

Third Quarter 2024 Financial Results

As of September 30, 2024, we had approximately $378.9 million in cash, cash equivalents, restricted cash and marketable securities. On a pro forma basis, including gross proceeds from the upfront payment under the Royalty Pharma Agreement and the first tranche of the Pharmakon loan and after repayment of our existing debt, we had approximately $542.4 million in cash, cash equivalents, restricted cash, and marketable securities as of September 30, 2024.

Net Loss

For the three and nine months ended September 30, 2024, the Company reported a net loss of $26.4 million, or $0.04 per share, and $149.2 million, or $0.23 per share, respectively, compared to $44.8 million, or $0.08 per share and $132.2 million, or $0.23 per share, respectively, for the three and nine months ended September 30, 2023.

Revenues

Total product revenue, net for the three and nine months ended September 30, 2024, was $28.2 million and $29.0 million, respectively.

Total net revenue for the three and nine months ended September 30, 2024, was $28.3 million and $29.5 million, respectively, compared to $164,000 and $214,000 for the same periods in 2023. The increase in revenue is due to product revenue from U.S. sales of RYTELO, which was available for prescribers to order from specialty distributors as of June 27, 2024.

Operating Expenses

Total operating expenses for the three and nine months ended September 30, 2024, were $56.5 million and $183.1 million, respectively, compared to $47.8 million and $139.9 million for the same periods in 2023.

Cost of goods sold was approximately $456,000 and $473,000 for the three and nine months ended September 30, 2024, respectively, which consisted of costs to manufacture and distribute RYTELO.

Research and development expenses for the three months and nine months ended September 30, 2024, were $20.2 million and $80.3 million, respectively, and $29.4 million and $92.1 million, for the same periods in 2023. The decrease is primarily due to manufacturing and quality costs that were capitalized in the current period due to FDA approval of RYTELO, compared to being expensed in the prior period.

Selling, general and administrative expenses for the three and nine months ended September 30, 2024, were $35.9 million, and $102.4 million, respectively, and $18.4 million and $47.7 million for the same periods in 2023. The increase in selling, general and administrative expenses primarily reflects higher commercial launch expenses, and increases in headcount and related expenses in connection with the U.S. launch of RYTELO.

Interest income was $4.9 million and $14.4 million for the three and nine months ended September 30, 2024, respectively, compared to $5.0 million and $13.6 million for the same periods in 2023. The decrease in interest income for the three months ended September 30, 2024, compared to the same period in 2023 was due to a decrease in interest rates. The increase in interest income for the nine months ended September 30, 2024, compared to the same period in 2023 primarily reflects a larger marketable securities portfolio with the receipt of net cash proceeds from the underwritten offering completed in March 2024, as well as higher yields from recent marketable securities purchases.

Interest expense was $3.0 million and $9.8 million for the three and nine months ended September 30, 2024, respectively, compared to $2.1 million and $6.0 million for the same periods in 2023. The increase in interest expense primarily reflects rising interest rates.

2024 Financial Guidance

For fiscal year 2024, we expect total operating expenses to be in the range of approximately $260 million to $270 million, which includes non-cash items such as stock-based compensation expense, amortization of debt discounts and issuance costs, and depreciation and amortization.

Based on our current operating plans and assumptions, we believe that our existing cash, cash equivalents, and marketable securities (including the $250 million gross proceeds received under the Pharmakon loan and Royalty Pharma agreements), together with anticipated revenues from U.S. sales of RYTELO, will be sufficient to fund our projected operating requirements for at least the next 12 months from the date of this press release. We believe that our projected financial resources will be sufficient to support commercial launch of RYTELO in the U.S. and potential launch in the EU, complete the Phase 3 IMpactMF trial in relapsed/refractory MF, invest in supply chain redundancy for RYTELO, and fund our general working capital requirements.

Conference Call

Geron will host a conference call at 8:00 a.m. ET on Thursday, November 7, 2024, to discuss business updates and third quarter financial results.

A live webcast of the conference call and related presentation will be available on the Company’s website at www.geron.com/investors/events. An archive of the webcast will be available on the Company’s website for 30 days.

Participants may access the webcast by registering online using the following link, https://events.q4inc.com/attendee/539655875

About RYTELO (imetelstat)

RYTELO (imetelstat) is an FDA-approved oligonucleotide telomerase inhibitor for the treatment of adult patients with low-to-intermediate-1 risk myelodysplastic syndromes (LR-MDS) with transfusion-dependent anemia requiring four or more red blood cell units over eight weeks who have not responded to or have lost response to or are ineligible for erythropoiesis-stimulating agents (ESAs). It is indicated to be administered as an intravenous infusion over two hours every four weeks.

RYTELO is a first-in-class treatment that works by inhibiting telomerase enzymatic activity. Telomeres are protective caps at the end of chromosomes that naturally shorten each time a cell divides. In LR-MDS, abnormal bone marrow cells often express the enzyme telomerase, which rebuilds those telomeres, allowing for uncontrolled cell division. Developed and exclusively owned by Geron, RYTELO is the first and only telomerase inhibitor approved by the U.S. Food and Drug Administration.

About Geron

Geron is a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer. Our first-in-class telomerase inhibitor RYTELO™ (imetelstat) is approved in the United States for the treatment of certain adult patients with lower-risk myelodysplastic syndromes (LR-MDS) with transfusion dependent anemia. We are also conducting a pivotal Phase 3 clinical trial of imetelstat in JAK-inhibitor relapsed/refractory myelofibrosis (R/R MF), as well as studies in other myeloid hematologic malignancies. Inhibiting telomerase activity, which is increased in malignant stem and progenitor cells in the bone marrow, aims to reduce proliferation and induce death of malignant cells. To learn more, visit www.geron.com or follow us on LinkedIn.

About IMpactMF Phase 3

IMpactMF is an open label, randomized, controlled Phase 3 clinical trial with registrational intent. The trial is designed to enroll approximately 320 patients with intermediate-2 or high-risk myelofibrosis (MF) who are relapsed after or refractory to prior treatment with a JAK inhibitor, also referred to as relapsed/refractory MF. Patients will be randomized to receive either imetelstat or best available therapy. The primary endpoint is overall survival (OS). Key secondary endpoints include symptom response, spleen response, progression free survival, complete remission, partial remission, clinical improvement, duration of response, safety, pharmacokinetics, and patient reported outcomes. IMpactMF is currently enrolling patients. For further information about IMpactMF, including enrollment criteria, locations and current status, visit ClinicalTrials.gov/NCT04576156.

IMPORTANT SAFETY INFORMATION ABOUT RYTELO

WARNINGS AND PRECAUTIONS

Thrombocytopenia

RYTELO can cause thrombocytopenia based on laboratory values. In the clinical trial, new or worsening Grade 3 or 4 decreased platelets occurred in 65% of patients with MDS treated with RYTELO.

Monitor patients with thrombocytopenia for bleeding. Monitor complete blood cell counts prior to initiation of RYTELO, weekly for the first two cycles, prior to each cycle thereafter, and as clinically indicated. Administer platelet transfusions as appropriate. Delay the next cycle and resume at the same or reduced dose, or discontinue as recommended.

Neutropenia

RYTELO can cause neutropenia based on laboratory values. In the clinical trial, new or worsening Grade 3 or 4 decreased neutrophils occurred in 72% of patients with MDS treated with RYTELO.

Monitor patients with Grade 3 or 4 neutropenia for infections, including sepsis. Monitor complete blood cell counts prior to initiation of RYTELO, weekly for the first two cycles, prior to each cycle thereafter, and as clinically indicated. Administer growth factors and anti-infective therapies for treatment or prophylaxis as appropriate. Delay the next cycle and resume at the same or reduced dose, or discontinue as recommended.

Infusion-Related Reactions

RYTELO can cause infusion-related reactions. In the clinical trial, infusion-related reactions occurred in 8% of patients with MDS treated with RYTELO; Grade 3 or 4 infusion-related reactions occurred in 1.7%, including hypertensive crisis (0.8%). The most common infusion-related reaction was headache (4.2%). Infusion-related reactions usually occur during or shortly after the end of the infusion.

Premedicate patients at least 30 minutes prior to infusion with diphenhydramine and hydrocortisone as recommended and monitor patients for one hour following the infusion as recommended. Manage symptoms of infusion-related reactions with supportive care and infusion interruptions, decrease infusion rate, or permanently discontinue as recommended.

Embryo-Fetal Toxicity

RYTELO can cause embryo-fetal harm when administered to a pregnant woman. Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment with RYTELO and for 1 week after the last dose.

ADVERSE REACTIONS

Serious adverse reactions occurred in 32% of patients who received RYTELO. Serious adverse reactions in >2% of patients included sepsis (4.2%) and fracture (3.4%), cardiac failure (2.5%), and hemorrhage (2.5%). Fatal adverse reactions occurred in 0.8% of patients who received RYTELO, including sepsis (0.8%).

Most common adverse reactions (≥10% with a difference between arms of >5% compared to placebo), including laboratory abnormalities, were decreased platelets, decreased white blood cells, decreased neutrophils, increased AST, increased alkaline phosphatase, increased ALT, fatigue, prolonged partial thromboplastin time, arthralgia/myalgia, COVID-19 infections, and headache.

Please see RYTELO (imetelstat) full Prescribing Information, including Medication Guide, available at https://pi.geron.com/products/US/pi/rytelo_pi.pdf.

Use of Forward-Looking Statements

Except for the historical information contained herein, this press release contains forward-looking statements made pursuant to the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such statements, include, without limitation, those regarding: (i) the Company’s expectations about the U.S. launch of RYTELO, its execution as a commercial company, the high unmet need in lower-risk MDS, and the compelling value proposition of RYTELO for hematologists and patients; (ii) the Company’s confidence in future continued demand and momentum for RYTELO; (iii) the Company’s view that the terms in the recently closed synthetic royalty and debt financing transactions reflect the significant commercial potential of RYTELO and provide the Company with critical flexibility to fuel continued growth and invest in its future; (iv) the Company’s expectations for the timing and completion of regulatory review and approval of RYTELO in the EU and, subject to regulatory approval, the Company’s plans to commercialize RYTELO in select EU markets commencing in 2026; (v) that the interim analysis of IMpactMF is expected in early 2026 and the final analysis is expected in early 2027; (vi) the Company’s projections and expectations regarding the sufficiency of its financial resources to fund its projected operating requirements for at least the next 12 months from the date of this release, including the sufficiency and use of the Company’s financial resources to support specified activities, and the assumptions underlying such projections and expectations; (vii) the Company’s projections for total operating expenses for fiscal 2024; (viii) that inhibiting telomerase activity aims to potentially reduce proliferation and induce death of malignant cells; (ix) that IMpactMF has registrational intent; and (x) other statements that are not historical facts, constitute forward-looking statements. These forward-looking statements involve risks and uncertainties that can cause actual results to differ materially from those in such forward-looking statements. These risks and uncertainties, include, without limitation, risks and uncertainties related to: (a) whether Geron is successful in commercializing RYTELO (imetelstat) for the treatment of certain patients with LR-MDS with transfusion dependent anemia; (b) whether Geron overcomes potential delays and other adverse impacts caused by enrollment, clinical, safety, efficacy, technical, scientific, intellectual property, manufacturing and regulatory challenges in order to have the financial resources for and meet expected timelines and planned milestones; (c) whether regulatory authorities permit the further development of imetelstat on a timely basis, or at all, without any clinical holds; (d) whether any future safety or efficacy results of imetelstat treatment cause the benefit-risk profile of imetelstat to become unacceptable; (e) whether imetelstat actually demonstrates disease-modifying activity in patients and the ability to target the malignant stem and progenitor cells of the underlying disease; (f) that Geron may seek to raise substantial additional capital in order to continue the development and commercialization of imetelstat; (g) whether Geron meets its post-marketing requirements and commitments in the U.S. for RYTELO for the treatment of patients with LR-MDS with transfusion dependent anemia; (h) whether there are failures or delays in manufacturing or supplying sufficient quantities of imetelstat or other clinical trial materials that impact commercialization of RYTELO for the treatment of patients with LR-MDS with transfusion dependent anemia or the continuation of the IMpactMF trial; (i) that the projected timing for the interim and final analyses of the IMpactMF trial may vary depending on actual enrollment and death rates in the trial; (j) whether Geron stays in compliance with and satisfies its obligations under its debt and royalty financing agreements; and (i) whether the European Commission will approve RYTELO for the treatment of patients with LR-MDS with transfusion dependent anemia and whether the FDA and European Commission will approve imetelstat for other indications on the timelines expected, or at all. Additional information on the above risks and uncertainties and additional risks, uncertainties and factors that could cause actual results to differ materially from those in the forward-looking statements are contained in Geron’s filings and periodic reports filed with the Securities and Exchange Commission under the heading “Risk Factors” and elsewhere in such filings and reports, including Geron’s quarterly report on Form 10-Q for the quarter ended June 30, 2024, and subsequent filings and reports by Geron. Undue reliance should not be placed on forward-looking statements, which speak only as of the date they are made, and the facts and assumptions underlying the forward-looking statements may change. Except as required by law, Geron disclaims any obligation to update these forward-looking statements to reflect future information, events, or circumstances.

Financial table follows.

GERON CORPORATION

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

 

 

 

 

Three Months Ended

Nine Months Ended

 

September 30,

September 30,

(In thousands, except share and per share data)

2024

 

2023

 

2024

 

2023

 

 

(Unaudited)

(Unaudited)

(Unaudited)

(Unaudited)

Revenues:

 

 

 

 

Product revenue, net

$

28,209

 

$

-

 

$

28,989

 

$

-

 

Royalties

 

62

 

 

164

 

 

468

 

 

214

 

 

 

28,271

 

 

164

 

 

29,457

 

 

214

 

Operating expenses:

 

 

 

 

 

 

 

 

Cost of goods sold

 

456

 

 

-

 

 

473

 

 

-

 

Research and development

 

20,153

 

 

29,426

 

 

80,305

 

 

92,135

 

Selling, general and administrative

 

35,877

 

 

18,350

 

 

102,361

 

 

47,734

 

Total operating expenses

 

56,486

 

 

47,776

 

 

183,139

 

 

139,869

 

 

 

 

 

 

 

 

 

 

Loss from Operations

 

(28,215

)

 

(47,612

)

 

(153,682

)

 

(139,655

)

 

 

 

 

 

 

 

 

 

Interest income

 

4,877

 

 

4,965

 

 

14,448

 

 

13,556

 

Interest expense

 

(3,046

)

 

(2,066

)

 

(9,798

)

 

(5,991

)

Other income and (expense), net

 

(63

)

 

(92

)

 

(188

)

 

(64

)

Net loss

$

(26,447

)

$

(44,805

)

$

(149,220

)

$

(132,154

)

 

 

 

 

 

 

 

 

 

Basic and diluted net loss per share:

 

 

 

 

 

 

 

 

Net loss per share

$

(0.04

)

$

(0.08

)

$

(0.23

)

$

(0.23

)

Shares used in computing net loss per share

 

662,158,182

 

 

579,508,305

 

 

639,933,612

 

 

562,445,577

 

CONDENSED CONSOLIDATED BALANCE SHEETS

 

 

 

September 30,

 

 

December 31,

 

(In thousands)

 

2024

 

 

2023

 

 

 

(Unaudited)

 

 

(Note 1)

 

Current assets:

 

 

 

 

 

 

Cash, cash equivalents and restricted cash

 

$

62,198

 

 

$

71,138

 

Current marketable securities

 

 

279,430

 

 

 

263,676

 

Other current assets

 

 

56,429

 

 

 

6,534

 

Total current assets

 

 

398,057

 

 

 

341,348

 

 

 

 

 

 

 

 

Noncurrent marketable securities

 

 

37,312

 

 

 

43,298

 

Property and equipment, net

1,595

1,177

Deposits and other assets

 

 

7,986

 

 

 

8,253

 

 

 

$

444,950

 

 

$

394,076

 

 

 

 

 

 

 

 

Current liabilities

 

$

137,933

 

 

$

108,070

 

Noncurrent liabilities

 

 

14,733

 

 

 

38,057

 

Stockholders’ equity

 

 

292,284

 

 

 

247,949

 

 

 

$

444,950

 

 

$

394,076

 

Note 1:

Derived from audited financial statements included in the Company’s annual report on Form 10-K for the year ended December 31, 2023.

 

Aron Feingold

Vice President, Investor Relations and Corporate Communications

Kristen Kelleher

Associate Director, Investor Relations and Corporate Communications

investor@geron.com

media@geron.com

Source: Geron Corporation

FAQ

What was Geron's (GERN) RYTELO revenue in Q3 2024?

Geron reported $28.2 million in RYTELO net product revenue for Q3 2024, its first full quarter of sales.

How much financing did Geron (GERN) secure in November 2024?

Geron secured $250 million through synthetic royalty and debt financing transactions with Royalty Pharma and Pharmakon Advisors, with access to an additional $125 million in debt.

What is Geron's (GERN) cash position as of Q3 2024?

Geron had $378.9 million in cash, cash equivalents, restricted cash and marketable securities, with pro forma cash of $542.4 million including recent financing proceeds.

What are Geron's (GERN) projected operating expenses for 2024?

Geron expects total operating expenses to be between $260 million to $270 million for fiscal year 2024.

Geron Corp

NASDAQ:GERN

GERN Rankings

GERN Latest News

GERN Stock Data

2.58B
602.80M
0.09%
78.25%
13.08%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
FOSTER CITY